Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer/GSK Levitra Sales Top $100 Mil.; New ED Patient Share Growing

Executive Summary

More than 40% of new prescriptions for Bayer/ GlaxoSmithKline's Levitra are for previously undiagnosed erectile dysfunction patients, Bayer CFO Klaus Kuhn told investors Nov. 11

You may also be interested in...



Bayer Focuses Internally: In-Licensing, In-House R&D Are Priorities

Bayer will focus on seeking licensing deals for its pharmaceutical business after abandoning a search for a more extensive partnership, CEO Werner Wenning told analysts Nov. 11

Quarterly Call Round-Up: Pfizer, GSK, Lilly Updates

Pfizer sees more savings from Pharmacia: Pfizer is now projecting "at least" $1 bil. in synergies from the Pharmacia acquisition in 2003, indicating that it expects to exceed its original target of $1 bil. in first-year savings...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

PS042820

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel